Samsung Epis Holdings Co., Ltd.
KKRX:0126Z0332,000.00
KRW
+4,000.00
(+1.22%)
ISIN
KR70126Z0002
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Kyung-Ah Kim
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Songdogyoyuk-ro Inchon GY South Korea South Korea
- IPO Date
- Nov 24, 2025
- Website
- samsungepisholdings.com
- Similar Companies
- Business
- Samsung Epis Holdings Co., Ltd. is an investment holding company focused on biopharmaceutical strategy and growth, including the management and advancement of biosimilar and next-generation biotechnology assets. Headquartered in Incheon, South Korea, the company was established in 2025 and operates as the parent entity for leading biotechnology subsidiaries, notably Samsung Bioepis, a premier biosimilars developer and producer, and Epis NexLab, a platform-focused arm dedicated to creating next-generation biotech technologies and therapeutic modalities. The group’s core business activities center on strategy development, portfolio management, and value creation across its biosimilar and early-stage biotechnology platforms, with a global footprint spanning multiple markets through its subsidiaries. Main products and services include: biosimilar therapeutics development, manufacturing, and commercialization; research and development activities across immunology, oncology, ophthalmology, hematology, nephrology, endocrinology, and related therapeutic areas; platform technology development for next-generation biologics and biotechnology platforms; licensing and collaboration arrangements for biosimilar and novel biologics with global pharmaceutical partners; portfolio optimization and strategic oversight of subsidiary operations; regulatory and quality assurance support enabling global product approvals and market access; supply chain and distribution services for biologics through Samsung Bioepis’ global network; and ongoing strategic investments in new subsidiaries and research programs to expand the company’s biotechnology ecosystem. Latest major company changes include: the spin-off from Samsung Biologics and subsequent establishment as an independent investment holding company in 2025; planned initial listing on the Korea Exchange (KRX) in late November 2025; formation of a new subsidiary to house next-generation biotechnology platforms while Samsung Bioepis continues as a wholly owned subsidiary; a series of strategic partnerships and licensing agreements to expand obesity treatment research and development through joint efforts with partner entities; and ongoing organizational realignment to optimize growth drivers and resource allocation across the biosimilar portfolio and new platform ventures. Additional context: Samsung Epis Holdings operates within the bio/pharma industry with two primary segments: biosimilars (via Samsung Bioepis) and next-generation biotechnology platforms (via Epis NexLab and related ventures). Target customers include global pharmaceutical companies, healthcare providers, and patients requiring access to high-quality biologics. Geographic operations span Korea and international markets through its subsidiaries’ manufacturing, regulatory, and commercial activities. Founding year is 2025 with headquarters in Incheon, South Korea, and the corporate structure includes wholly owned subsidiary Samsung Bioepis and a developing subsidiary focused on next-generation biotech platforms, forming part of a broader ecosystem aimed at accelerating biosimilar access and innovative therapeutics.